The $2 trillion stimulus packaged passed unanimously by the US Senate this morning will have important implications for the dietary supplement industry that may help companies survive the worst of the coronavirus crisis impacts.
Synthetic astaxanthin product developer Cardax has released a white paper and reportedly filed a patent application on the ingredient’s antiviral properties and in publicizing the fact has treaded on the disease claim line according to legal experts.
Dietary supplement manufacturers and the natural channel stores that sell the products play an important role in supporting consumers health during this challenging time and should be counted as ‘essential’ businesses, stakeholders say.
While the COVID-19 crisis dominates headlines, a raft of state and local laws that could negatively affect the dietary supplement industry are afoot and deserve attention, according the Council for Responsible Nutrition.
As the news about COVID-19 becomes ever more sobering, the question becomes what dietary supplements might do to help. I think there is opportunity here, but talking about it requires walking a tightrope over a gulf of regulatory peril.
The German Food and Agriculture Ministry (BMEL) has refuted an EU hemp group missive that the Ministry had changed its position regarding the novel food requirement for some cannabidiol (CBD) extracts in the EU.
Contract manufacturer Icelandirect has announced it has achieved organic certification, the company announced recently, which is part of a trend of widening organic options with the dietary supplement industry.
The US Food and Drug Administration has sent warning letters to seven companies that have been alleged to have been making COVID-19 disease treatment claims. Among the recipients of the warning letters is a prominent televangelist.